Core Viewpoint - The "2024-2025 Family Essential Medicine Brand Awards" event recognized key pharmaceutical brands, emphasizing the importance of quality and consumer trust in the healthcare sector [1][2] Group 1: Event Overview - The award ceremony took place on November 18 during the "91st National Pharmaceutical Trade Fair" in Nanjing, highlighting its status as a benchmark in family health medication [1] - The selection process involved rigorous qualification checks, market surveys, public voting, and professional evaluations to ensure product quality and reputation [1] Group 2: Company Achievements - Linuo Pharmaceutical won three significant awards, including the "Consumer Favorite Enterprise Award," showcasing its brand strength and market reputation [1] - The company's core product, Furuisi Ammonium Lignosulfonate Paste, was recognized as a top brand in the "Oral and Throat Medicine" category, while the Xinshu Nitroglycerin Spray was listed in the "Cardiovascular Medicine" category [1] Group 3: Company Background and Future Plans - Established in 2002, Linuo Pharmaceutical is a wholly-owned subsidiary of Kexin Pharmaceutical (stock code: 301281.SZ) and is recognized as a high-tech enterprise with significant growth potential in the Chinese pharmaceutical industry [1][2] - The company has accelerated its digital transformation, establishing three intelligent manufacturing bases and creating a diverse product matrix, which includes various dosage forms [2] - Future plans include continuous product upgrades and innovative research to align with the "Healthy China" strategy, aiming to enhance public health and maintain consumer trust [2]

北京世辉律师事务所 关于山东科源制药股份有限公司 2025 年第四次临时股东会的 法律意见书 致：山东科源制药股份有限公司 北京世辉律师事务所（以下简称"本所"）为具有从事法律业务资格的律师事 务所。本所接受山东科源制药股份有限公司（以下简称"公司"）的委托，指派本 所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司股东会规则》等有关法律、法规、规范性文件（以下统称 "法律法规"）及《山东科源制药股份有限公司章程》（以下简称"《公司章程》"） 的规定，就公司 2025 年第四次临时股东会（以下简称"本次股东会"）相关事宜 出具本法律意见书。 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、 完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大 遗漏，并承担相应法律责任。 经本所律师核查，本所律师认为，本次股东会的召集 ...

证券代码：301281 证券简称：科源制药 公告编号：2025-078 山东科源制药股份有限公司 2025 年第四次临时股东会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形； 2、本次股东会涉及变更以往股东会已通过的决议。本次股东会审议通过了 《关于募集资金投资项目变更的议案》，同意公司根据整体规划，对已经2024 年第二次临时股东大会审议通过的《关于使用超募资金及自有资金投资建设"高 端特色中间体及原料药智能制造项目（一期项目）"的议案》中的募集资金投资 项目等进行调整。 1、现场会议召开时间：2025年11月19日（星期三）15:30。 2、现场会议召开地点：山东省济南市历城区经十东路30766号力诺智慧园山 东力诺制药有限公司第二会议室。 3、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年11月19 日9:15-9:25，9:30—11:30，13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年11月19日 9:15—15:00 ...

中信建投证券股份有限公司 关于山东科源制药股份有限公司 部分募集资金投资项目变更的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券""保荐人"）为山东科 源制药股份有限公司（以下简称"科源制药""公司"）首次公开发行股票并在创业 板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监 管规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号—创业板上市公司规范运作》等有关规定，对公司部分募投项目 变更的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东科源制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕362 号）同意注册，并经深圳证券交 易所同意，公司首次向社会公众公开发行人民币普通股（A 股）1,935.00 万股， 每股发行价 44.18 元，募集资金总额为人民币 854,883,000.00 元，扣除发行费用 89,961,225.68 元，募集资金净额为人民币 764,921,774.32 元。上述资金已全部到 位，经信永中和会计师事务所（特殊普通合伙）验证，并于 2023 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 10 月 31 日召 开第四届董事会第十四次会议，审议通过了《关于募集资金投资项目变更的议案》， 综合考虑当前募投项目的实施情况，为充分发挥募集资金使用效果，公司同意变 更部分募投项目内容。上述事项尚需提交股东会审议。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东科源制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕362 号）同意注册，并经深圳证券交 易所同意，公司首次向社会公众公开发行人民币普通股（A 股）1,935.00 万股， 每股发行价 44.18 元，募集资金总额为人民币 854,883,000.00 元，扣除发行费 用 89,961,225.68 元，募集资金净额为人民币 764,921,774.32 元。上述资金已 全部到位，经信永中和会计师事务所（特殊普通合伙）验证，并于 2023 年 3 月 30 日出具 XYZH/2023JNAA5B0068 号《验资报告》。 为规范公司募集 ...

山东科源制药股份有限公司 关于召开 2025 年第四次临时股东会的通知 证券代码：301281 证券简称：科源制药 公告编号：2025-077 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2025 年 10 月 31 日召开第四届董事会第十四 次会议，审议通过了《关于提请召开 2025 年第四次临时股东会的议案》，公司董事会决定于 2025 年 11 月 19 日 15:30 以现场投票与网络投票相结合的方式召开公司 2025 年第四次临时股东会（以下简称 "本次股东会"），现将会议的有关情况通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第四次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 19 日 15:30 （ ...

山东科源制药股份有限公司 第四届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东科源制药股份有限公司（以下简称"公司"）第四届董事会第十四次会 议通知已于 2025 年 10 月 28 日通过电子邮件等方式送达全体董事，经全体董事 一致同意，本次会议已豁免通知期限要求。会议于 2025 年 10 月 31 日以现场和 通讯表决相结合方式在公司会议室召开。会议由董事长高春坡先生主持，本次会 议应出席董事 7 名，实际出席董事 7 名，邹晓虹先生、武滨先生通过通讯方式参 会。公司高级管理人员列席了会议。本次会议的召开和表决程序符合《中华人民 共和国公司法》等法律、法规、规范性文件和《公司章程》的有关规定，会议合 法、有效。经公司全体董事审议通过如下议案： 二、董事会会议审议情况 1、审议通过了《关于豁免公司第四届董事会第十四次会议通知期限的议案》 证券代码：301281 证券简称：科源制药 公告编号：2025-075 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于 募集资金 ...

Core Viewpoint - Key financial metrics for Koyuan Pharmaceutical indicate a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters reached 303 million yuan, representing a year-on-year decrease of 8.52% [1] - The net profit attributable to shareholders of the listed company was 31.47 million yuan, down 20.69% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 22.65 million yuan, reflecting a year-on-year decrease of 15.84% [1] - Basic earnings per share stood at 0.2906 yuan [1]

Core Viewpoint - Key financial metrics for Koyuan Pharmaceutical indicate a decline in both revenue and net profit for the first three quarters of the year, suggesting potential challenges in the company's performance [1] Financial Performance - The company's operating revenue for the first three quarters reached 300 million, representing a year-on-year decrease of 8.52% [1] - The net profit attributable to shareholders of the listed company was 31.47 million, down 20.69% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 22.65 million, reflecting a year-on-year decline of 15.84% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥74,822,074.87, a decrease of 20.18% compared to the same period last year[5] - The net profit attributable to shareholders was -¥11,212,366.34, representing a decline of 417.79% year-on-year[5] - The basic earnings per share were -¥0.1035, down 411.75% from the previous year[5] - Total operating revenue for the current period is CNY 302,688,076.14, a decrease of 8.5% from CNY 330,879,995.68 in the previous period[25] - Operating profit for the current period is CNY 28,023,489.32, a decrease of 38.9% compared to CNY 45,779,440.84 in the previous period[25] - The total profit for the current period is 31,944,668.70, a decrease from 42,917,141.46 in the previous period, representing a decline of approximately 25.0%[26] - The net profit attributable to the parent company's shareholders is 31,470,676.81, down from 39,683,076.25, reflecting a decrease of about 20.5%[26] - The basic and diluted earnings per share for the current period are both 0.2906, compared to 0.3665 in the previous period, indicating a decline of approximately 20.7%[26] - The company reported a total comprehensive income of 31,261,045.17, down from 39,555,461.09, representing a decrease of approximately 21.0%[26] Assets and Liabilities - Total assets increased by 3.44% to ¥1,605,846,303.20 compared to the end of the previous year[5] - Total assets increased to CNY 1,605,846,303.20 from CNY 1,552,474,271.14, an increase of 3.4%[22] - Total liabilities increased to CNY 234,398,997.89 from CNY 192,870,734.45, an increase of 21.5%[22] - Non-current liabilities increased to CNY 121,851,690.85 from CNY 73,085,908.60, an increase of 66.5%[22] - The company's retained earnings increased to CNY 299,866,341.34 from CNY 290,053,664.53, an increase of 3.3%[22] Cash Flow - The cash flow from operating activities for the year-to-date was ¥27,239,921.33, an increase of 14.11%[5] - Cash flow from operating activities for the current period is 27,239,921.33, an increase from 23,870,916.56 in the previous period, showing a growth of about 14.3%[28] - Cash flow from investing activities shows a net outflow of -129,634,477.79, worsening from -49,669,863.98 in the previous period[28] - Cash flow from financing activities has a net inflow of 27,968,645.03, compared to a net outflow of -31,487,820.72 in the previous period, indicating a significant turnaround[29] - The total cash and cash equivalents at the end of the period is 17,832,571.09, down from 267,304,173.29, a decrease of approximately 93.3%[29] - The company received cash from sales of goods and services amounting to 202,183,174.02, a decrease from 253,258,899.75 in the previous period, reflecting a decline of about 20.2%[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,085[14] - The largest shareholder, Linuo Investment Holding Group Co., Ltd., holds 34.39% of shares, totaling 37,240,000 shares, with 29,340,000 shares pledged[14] - Jinan Anfu Venture Investment Partnership holds 5.82% of shares, totaling 6,300,000 shares, with 3,380,000 shares pledged[14] - The second-largest shareholder, Wen Zehong, holds 5.00% of shares, totaling 5,414,500 shares[14] - Jinan Financial Technology Investment Co., Ltd. holds 4.72% of shares, totaling 5,110,000 shares[14] - The company has a significant concentration of ownership, with the top 10 shareholders holding a substantial portion of shares[15] - The company has a diverse shareholder base, including both state-owned and private entities[15] Investment and Acquisitions - The company plans to issue shares to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 counterparties[18] - The company intends to raise matching funds by issuing shares to no more than 35 qualified investors[18] Other Financial Metrics - Research and development expenses rose by 58.75% to ¥35,488,296.63 for the year-to-date[11] - The company reported a significant increase in prepayments by 249.13% to ¥9,853,603.83 due to increased procurement payments[11] - The company experienced a 70.58% increase in accounts receivable, totaling ¥91,443,182.78, attributed to extended credit terms[11] - The company recorded a substantial increase in other income, which rose by 8,576.46% to ¥5,121,585.72, primarily from non-recurring government subsidies[12] - Cash and cash equivalents decreased to CNY 74,832,571.09 from CNY 178,129,204.25, a decline of 58.0%[21] - Accounts receivable increased to CNY 91,443,182.78 from CNY 53,605,977.19, an increase of 70.5%[21] - Inventory increased to CNY 151,084,601.64 from CNY 128,944,612.45, an increase of 17.2%[21] - The company has not undergone an audit for the third quarter financial report[30]